Literature DB >> 2782764

The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial.

L H Kuller1, J K Ockene, M Townsend, W Browner, E Meilahn, D N Wentworth.   

Abstract

The potential determinants of the changes in chronic obstructive pulmonary disease (COPD) mortality were evaluated using both the Multiple Risk Factor Intervention Trial (MRFIT) screenees, the longitudinal analysis of the participants, and the differences in special intervention (SI) and usual care (UC) groups. COPD was the underlying cause for only one third of all death certificates listing COPD. Small changes in classification will have a major impact on reported COPD death rates. Cigarette smoking is clearly the primary determinant of COPD mortality. Decreased pulmonary function is an independent risk factor for coronary heart disease (CHD) mortality. Smoking cessation results in a slower rate of decline in pulmonary function over time, especially among heavy smokers. Careful evaluation of smoking cessation, including repeat chemical measures, suggest that the percentage of long-term quitters, especially among heavy smokers has been overestimated. The low percentage of quitters substantially reduced the power to detect an intervention effect. The increased cigarette smoking among recent older cohorts, and failure to substantially reduce smoking, especially among heavy smokers, may be an important factor accounting for the failure to note a decline in COPD mortality among older persons.

Entities:  

Mesh:

Year:  1989        PMID: 2782764     DOI: 10.1164/ajrccm/140.3_Pt_2.S76

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  16 in total

Review 1.  Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema.

Authors:  Barbara A Forey; Alison J Thornton; Peter N Lee
Journal:  BMC Pulm Med       Date:  2011-06-14       Impact factor: 3.317

Review 2.  Effective use of combination lipid therapy.

Authors:  Abu R Vasudevan; Peter H Jones
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

3.  Pulmonary Impairment and Risk Assessment in a Diacetyl-Exposed Population: Microwave Popcorn Workers.

Authors:  Robert M Park; Stephen J Gilbert
Journal:  J Occup Environ Med       Date:  2018-06       Impact factor: 2.162

4.  Association of lung function with coronary heart disease and cardiovascular disease outcomes in elderly: the Rancho Bernardo study.

Authors:  Hwa Mu Lee; Michael A Liu; Elizabeth Barrett-Connor; Nathan D Wong
Journal:  Respir Med       Date:  2014-10-06       Impact factor: 3.415

5.  Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers.

Authors:  Mark P Purdue; Laura Gold; Bengt Järvholm; Michael C R Alavanja; Mary H Ward; Roel Vermeulen
Journal:  Thorax       Date:  2006-08-23       Impact factor: 9.139

6.  Effective use of combination lipid therapy.

Authors:  Abu R Vasudevan; Peter H Jones
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

7.  Mortality in Glasgow and Edinburgh: a paradigm of inequality in health.

Authors:  G C Watt; R Ecob
Journal:  J Epidemiol Community Health       Date:  1992-10       Impact factor: 3.710

8.  Chronic obstructive pulmonary disease in lifelong nonsmokers: results from NHANES.

Authors:  A S Whittemore; S A Perlin; Y DiCiccio
Journal:  Am J Public Health       Date:  1995-05       Impact factor: 9.308

9.  Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients.

Authors:  T J Crowley; M J Macdonald; M I Walter
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

10.  Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age.

Authors:  Michael J Cuttica; Laura A Colangelo; Sanjiv J Shah; Joao Lima; Satoru Kishi; Alexander Arynchyn; David R Jacobs; Bharat Thyagarajan; Kiang Liu; Donald Lloyd-Jones; Ravi Kalhan
Journal:  Am J Respir Crit Care Med       Date:  2015-07-01       Impact factor: 30.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.